Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.

Aurer, Igor; Radman, Ivo; Nemet, Damir; Zupancic-Salek, Silva; Bogdanic, Vinko; Mrsic, Mirando; Sertic, Dubravka; Labar, Boris

Aurer, Igor; Radman, Ivo; Nemet, Damir; Zupancic-Salek, Silva; Bogdanic, Vinko; Mrsic, Mirando; Sertic, Dubravka; Labar, Boris.

Affiliation

Aurer I; Division of Hematology, Department of Internal Medicine, University Hospital Center Rebro and Medical School, Zagreb, Croatia. aurer@mef.hr

Onkologie ; 28(11): 567-71, 2005 Nov.

Article in En | MEDLINE | ID: mdl-16249642

Subject(s)

Deoxycytidine/analogs & derivatives; Hodgkin Disease/drug therapy; Hodgkin Disease/mortality; Neoplasm Recurrence, Local/epidemiology; Neoplasm Recurrence, Local/prevention & control; Risk Assessment/methods; Adolescent; Adult; Antimetabolites, Antineoplastic/administration & dosage; Antimetabolites, Antineoplastic/adverse effects; Croatia/epidemiology; Deoxycytidine/administration & dosage; Deoxycytidine/adverse effects; Disease-Free Survival; Female; Humans; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Failure; Treatment Outcome; Gemcitabine

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Risk Assessment / Deoxycytidine / Neoplasm Recurrence, Local Type of study: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Onkologie Year: 2005 Document type: Article Affiliation country: Croatia Country of publication: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links